Anavex Life Sciences Corp (AVXL)

[Investor2014]

“If new FDA guidelines require more comprehensive analysis and planning prior to P2/P3 then micro Biotec investing should be lower risk than in past. In fact, an objective retrospective review of the past 20+ yrs of AD trials data w/new analysis algo's would (should) show what is now obvious. They never had a chance.”

Better modelling and pre-planned analysis is the way forward.

We are now at an inflection point where the understanding, sophistication, detail and cost of analysis is beginning to make precision medicine the better financial choice over hope and pray type of trials with post hoc analysis paralysis trying to rescue some revenue from the remains of failed hypothesis and financial black holes.

I sincerely hope and actually believe Missling is keen to lead the way for CNS in this new direction.

Happy to give him a few more weeks or months to get it right. This is not just about money.